Direct
Sustainable Future
Optogenetics-and-AI drug discovery targeting the biology of aging.
Series A
Stage
July 2026
Invested
USA
HQ
WHAT THEY DO
A drug-discovery company building small-molecule therapeutics for age-related disease. Its platform pairs optogenetics (light-controlled, on-pathway perturbation of aging biology in living cells) with a large-scale in-vivo aging model and a custom AI chemistry stack co-developed with xAI, on the bet that proprietary, on-pathway data produces better molecules faster than conventional screening or pure structure prediction. Founded by Felix Wong (who led AI-driven antibiotic discovery at the Broad Institute/MIT), optogenetics pioneer Maxwell Wilson (UC Santa Barbara), and synthetic-biology founder James J. Collins (MIT), it runs preclinical programs across cardiometabolic disease, lipoprotein(a), oncology, and regenerative targets as expressions of a single discovery engine.
Cardiometabolic therapeutics, Lipoprotein(a) / CV disease, Oncology, Regenerative medicine, Pharma licensing & co-development
WHAT THEY DO
A drug-discovery company building small-molecule therapeutics for age-related disease. Its platform pairs optogenetics (light-controlled, on-pathway perturbation of aging biology in living cells) with a large-scale in-vivo aging model and a custom AI chemistry stack co-developed with xAI, on the bet that proprietary, on-pathway data produces better molecules faster than conventional screening or pure structure prediction. Founded by Felix Wong (who led AI-driven antibiotic discovery at the Broad Institute/MIT), optogenetics pioneer Maxwell Wilson (UC Santa Barbara), and synthetic-biology founder James J. Collins (MIT), it runs preclinical programs across cardiometabolic disease, lipoprotein(a), oncology, and regenerative targets as expressions of a single discovery engine.
WHAT THEY DO
A drug-discovery company building small-molecule therapeutics for age-related disease. Its platform pairs optogenetics (light-controlled, on-pathway perturbation of aging biology in living cells) with a large-scale in-vivo aging model and a custom AI chemistry stack co-developed with xAI, on the bet that proprietary, on-pathway data produces better molecules faster than conventional screening or pure structure prediction. Founded by Felix Wong (who led AI-driven antibiotic discovery at the Broad Institute/MIT), optogenetics pioneer Maxwell Wilson (UC Santa Barbara), and synthetic-biology founder James J. Collins (MIT), it runs preclinical programs across cardiometabolic disease, lipoprotein(a), oncology, and regenerative targets as expressions of a single discovery engine.
Cardiometabolic therapeutics, Lipoprotein(a) / CV disease, Oncology, Regenerative medicine, Pharma licensing & co-development
WHY WE INVESTED
We invested because aging sits upstream of most human disease and is finally becoming something you can drug rather than merely describe. Integrated brought together people who helped invent the relevant fields, synthetic biology, Nobel-recognized chemistry, landmark AI-antibiotic work, and built the platform that generates the clean biological data most drug discovery lacks.
WHY WE INVESTED
We invested because aging sits upstream of most human disease and is finally becoming something you can drug rather than merely describe. Integrated brought together people who helped invent the relevant fields, synthetic biology, Nobel-recognized chemistry, landmark AI-antibiotic work, and built the platform that generates the clean biological data most drug discovery lacks.
WHY WE INVESTED
We invested because aging sits upstream of most human disease and is finally becoming something you can drug rather than merely describe. Integrated brought together people who helped invent the relevant fields, synthetic biology, Nobel-recognized chemistry, landmark AI-antibiotic work, and built the platform that generates the clean biological data most drug discovery lacks.
IMPACT RELEVANCE
Applies AI-driven synthetic biology to the cellular stress pathways behind aging, expanding the drug-discovery toolkit for a disease burden that scales with an aging population, via reusable screening infrastructure rather than a single-asset bet.
CO-INVESTORS
